Spyre Therapeutics, Inc. (SYRE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Spyre Therapeutics, Inc. on March 6, 2025, covering events occurring on February 28, 2025. The Company is a Delaware corporation with its principal executive offices in Waltham, MA, and its common stock trades on the Nasdaq Global Select Market under the symbol "SYRE".
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on corporate governance changes regarding the independent registered public accounting firm.
Material Changes
- Dismissal of Auditor: On February 28, 2025, the Audit Committee dismissed PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm, effective immediately. PwC had served the Company since 2014.
- Appointment of New Auditor: On February 28, 2025, the Audit Committee appointed KPMG LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately.
- Reason for Change: The dismissal followed the identification of a material weakness as of December 31, 2024. This weakness involved the Company's failure to design and maintain effective controls to evaluate the treatment of Series A and Series B non-voting convertible preferred stock for earnings per share calculations under the two-class method. This issue resulted in a restatement of the consolidated financial statements for the year ended December 31, 2023.
- Audit Opinions: PwC's reports for fiscal years 2024 and 2023 did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed is the material weakness in internal controls over financial reporting related to preferred stock accounting, which necessitated a prior restatement and led to the change in auditors. The Company confirmed there were no disagreements with PwC on accounting principles or practices other than the noted material weakness.
Investor Verification Checklist
- Verify the details of the restatement for the fiscal year ended December 31, 2023, specifically regarding the two-class method for earnings per share.
- Review the letter from PwC (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the dismissal.
- Monitor upcoming filings for the transition of audit responsibilities from PwC to KPMG and any further disclosures regarding the remediation of the identified material weakness.
- Confirm that no other reportable events or disagreements existed between the Company and PwC during the two most recent fiscal years and the interim period through February 28, 2025.